Display options
Cite
Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021;27(12):2136-2143doi: 10.1038/s41591-021-01583-4.
Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., Al Kuwari, E., Jeremijenko, A., Kaleeckal, A. H., Latif, A. N., Shaik, R. M., Abdul Rahim, H. F., Nasrallah, G. K., Al Kuwari, M. G., Al Romaihi, H. E., Butt, A. A., Al-Thani, M. H., Al Khal, A., Bertollini, R., & Abu-Raddad, L. J. (2021). BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nature medicine, 27(12), 2136-2143. https://doi.org/10.1038/s41591-021-01583-4
Tang, Patrick, et al. "BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar." Nature medicine vol. 27,12 (2021): 2136-2143. doi: https://doi.org/10.1038/s41591-021-01583-4
Tang P, Hasan MR, Chemaitelly H, Yassine HM, Benslimane FM, Al Khatib HA, AlMukdad S, Coyle P, Ayoub HH, Al Kanaani Z, Al Kuwari E, Jeremijenko A, Kaleeckal AH, Latif AN, Shaik RM, Abdul Rahim HF, Nasrallah GK, Al Kuwari MG, Al Romaihi HE, Butt AA, Al-Thani MH, Al Khal A, Bertollini R, Abu-Raddad LJ. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 02. PMID: 34728831.
Copy Download .nbib Format: NLM
Share it on

Nat Med. 2021 Dec;27(12):2136-2143. doi: 10.1038/s41591-021-01583-4. Epub 2021 Nov 02.

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.

Nature medicine

Patrick Tang, Mohammad R Hasan, Hiam Chemaitelly, Hadi M Yassine, Fatiha M Benslimane, Hebah A Al Khatib, Sawsan AlMukdad, Peter Coyle, Houssein H Ayoub, Zaina Al Kanaani, Einas Al Kuwari, Andrew Jeremijenko, Anvar Hassan Kaleeckal, Ali Nizar Latif, Riyazuddin Mohammad Shaik, Hanan F Abdul Rahim, Gheyath K Nasrallah, Mohamed Ghaith Al Kuwari, Hamad Eid Al Romaihi, Adeel A Butt, Mohamed H Al-Thani, Abdullatif Al Khal, Roberto Bertollini, Laith J Abu-Raddad

Affiliations

  1. Department of Pathology, Sidra Medicine, Doha, Qatar.
  2. Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar.
  3. World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar.
  4. Biomedical Research Center, Member of QU Health, Qatar University, Doha, Qatar.
  5. Department of Biomedical Science, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar.
  6. Hamad Medical Corporation, Doha, Qatar.
  7. Wellcome-Wolfson Institute for Experimental Medicine, Queens University, Belfast, UK.
  8. Mathematics Program, Department of Mathematics, Statistics, and Physics, College of Arts and Sciences, Qatar University, Doha, Qatar.
  9. Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar.
  10. Primary Health Care Corporation, Doha, Qatar.
  11. Ministry of Public Health, Doha, Qatar.
  12. Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA.
  13. Infectious Disease Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Doha, Qatar. [email protected].
  14. World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation - Education City, Doha, Qatar. [email protected].
  15. Department of Public Health, College of Health Sciences, QU Health, Qatar University, Doha, Qatar. [email protected].
  16. Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York, NY, USA. [email protected].

PMID: 34728831 DOI: 10.1038/s41591-021-01583-4

Abstract

With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) ≥14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021. Corresponding mRNA-1273 effectiveness ≥14 d after the first or second dose was 73.7% (95% CI, 58.1-83.5%) and 73.1% (95% CI, 67.5-77.8%), respectively. Notably, effectiveness against Delta-induced severe, critical or fatal disease was 93.4% (95% CI, 85.4-97.0%) for BNT162b2 and 96.1% (95% CI, 71.6-99.5%) for mRNA-1273 ≥ 14 d after the second dose. Our findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT162b2 vaccine.

© 2021. The Author(s), under exclusive licence to Springer Nature America, Inc.

References

  1. National Project of Surveillance for Variants of Concern and Viral Genome Sequencing. Qatar viral genome sequencing data. Data on randomly collected samples. https://www.gisaid.org/phylodynamics/global/nextstrain/ (2021). - PubMed
  2. Benslimane, F. M. et al. One year of SARS-CoV-2: genomic characterization of COVID-19 outbreak in Qatar. Preprint at medRxiv https://doi.org/10.1101/2021.05.19.21257433 (2021). - PubMed
  3. Hasan, M. R. et al. Real-time SARS-CoV-2 genotyping by high-throughput multiplex PCR reveals the epidemiology of the variants of concern in Qatar. Int J. Infect. Dis. 112, 52–54 (2021). - PubMed
  4. Abu-Raddad, L. J., Chemaitelly, H., Butt, A. A. & National Study Group for COVID-19 Vaccination. Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants. N. Engl. J. Med. https://doi.org/10.1056/NEJMc2104974 (2021). - PubMed
  5. Chemaitelly, H. et al. mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar. Nat. Med 27, 1614–1621 (2021). - PubMed
  6. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020). - PubMed
  7. Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021). - PubMed
  8. Ministry of Public Health. National Covid-19 Testing and Vaccination Program Data. https://covid19.moph.gov.qa/EN/Pages/Vaccination-Program-Data.aspx (2021). - PubMed
  9. Abu-Raddad, L. J. et al. Characterizing the Qatar advanced-phase SARS-CoV-2 epidemic. Sci. Rep. 11, 6233 (2021). - PubMed
  10. Planning and Statistics Authority-State of Qatar. Qatar Monthly Statistics. https://www.psa.gov.qa/en/pages/default.aspx (2020). - PubMed
  11. World Health Organization. COVID-19 clinical management: living guidance. https://www.who.int/publications/i/item/WHO-2019-nCoV-clinical-2021-1 (2021). - PubMed
  12. World Health Organization. International guidelines for certification and classification (coding) of COVID-19 as cause of death. https://www.who.int/classifications/icd/Guidelines_Cause_of_Death_COVID-19-20200420-EN.pdf?ua=1 (2020). - PubMed
  13. Stowe, J. et al. Effectiveness of COVID-19 vaccines against hospital admission with the Delta (B.1.617.2) variant. https://khub.net/web/phe-national/public-library/-/document_library/v2WsRK3ZlEig/view_file/479607329?_com_liferay_document_library_web_portlet_DLPortlet_INSTANCE_v2WsRK3ZlEig_redirect=https%253A%252F%252Fkhub.net%253A443%252Fweb%252Fphe-national%252Fpublic-library%252F-%25 (2021). - PubMed
  14. Andrews, N. et al. Vaccine effectiveness and duration of protection of Comirnaty, Vaxzevria and Spikevax against mild and severe COVID-19 in the UK. https://khub.net/documents/135939561/338928724/Vaccine+effectiveness+and+duration+of+protection+of+covid+vaccines+against+mild+and+severe+COVID-19+in+the+UK.pdf/10dcd99c-0441-0403-dfd8-11ba2c6f5801 (2021). - PubMed
  15. Tenforde, M. W. et al. Sustained effectiveness of Pfizer-BioNTech and Moderna vaccines against COVID-19 associated hospitalizations among adults - United States, March–July 2021. Morb. Mortal. Wkly Rep. 70, 1156–1162 (2021). - PubMed
  16. Bajema, K. L. et al. Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalization - five Veterans Affairs Medical Centers, United States, February 1–August 6, 2021. Morb. Mortal. Wkly Rep. 70, 1294–1299 (2021). - PubMed
  17. Grannis, S. J. et al. Interim estimates of COVID-19 vaccine effectiveness against COVID-19-associated emergency department or urgent care clinic encounters and hospitalizations among adults during SARS-CoV-2 B.1.617.2 (Delta) variant predominance - nine states, June–August 2021. Morb. Mortal. Wkly Rep. 70, 1291–1293 (2021). - PubMed
  18. Tartof, S.Y. et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet https://doi.org/10.1016/S0140-6736(21)02183-8 (2021). - PubMed
  19. Israel Ministry of Health. COVID-19 vaccine effectiveness against the Delta variant. Israel’s Ministry of Health Report https://www.gov.il/BlobFolder/reports/vaccine-efficacy-safety-follow-up-committee/he/files_publications_corona_two-dose-vaccination-data.pdf (2021). - PubMed
  20. Israel, A. et al. Elapsed time since BNT162b2 vaccine and risk of SARS-CoV-2 infection in a large cohort. Preprint at medRxiv https://doi.org/10.1101/2021.08.03.21261496 (2021). - PubMed
  21. Thomas, S. J. et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine through 6 months. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2110345 (2021). - PubMed
  22. Mizrahi, B. et al. Correlation of SARS-CoV-2 breakthrough infections to time-from-vaccine: preliminary study. Preprint at medRxiv https://doi.org/10.1101/2021.07.29.21261317 (2021). - PubMed
  23. Chemaitelly, H. et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2114114 (2021). - PubMed
  24. Abu-Raddad, L. J. et al. Pfizer-BioNTech mRNA BNT162b2 Covid-19 vaccine protection against variants of concern after one versus two doses. J. Travel Med. https://doi.org/10.1093/jtm/taab083 (2021). - PubMed
  25. Bertollini, R. et al. Associations of vaccination and of prior infection with positive PCR test results for SARS-CoV-2 in airline passengers arriving in Qatar. JAMA 326, 185–188 (2021). - PubMed
  26. Lopez Bernal, J. et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2108891 (2021). - PubMed
  27. Sheikh, A., McMenamin, J., Taylor, B. & Robertson, C. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet 397, 2461–2462 (2021). - PubMed
  28. Nasreen, S. et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada. Preprint at medRxiv https://doi.org/10.1101/2021.06.28.21259420 (2021). - PubMed
  29. Puranik, A. et al. Comparison of two highly effective mRNA vaccines for COVID-19 during periods of Alpha and Delta variant prevalence. Preprint at medRxiv https://doi.org/10.1101/2021.08.06.21261707 (2021). - PubMed
  30. Fowlkes, A. et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2 (Delta) variant predominance - eight US locations, December 2020–August 2021. Morb. Mortal. Wkly Rep. 70, 1167–1169 (2021). - PubMed
  31. Nanduri, S. et al. Effectiveness of Pfizer-BioNTech and Moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2 (Delta) variant - National Healthcare Safety Network, March 1–August 1, 2021. Morb. Mortal. Wkly Rep. 70, 1163–1166 (2021). - PubMed
  32. Makhoul, M. et al. Epidemiological impact of SARS-CoV-2 vaccination: mathematical modeling analyses. Vaccines https://doi.org/10.3390/vaccines8040668 (2020). - PubMed
  33. Usherwood, T., LaJoie, Z. & Srivastava, V. A model and predictions for COVID-19 considering population behavior and vaccination. Sci. Rep. 11, 12051 (2021). - PubMed
  34. Andersson, O., Campos-Mercade, P., Meier, A.N. & Wengström, E. Anticipation of COVID-19 vaccines reduces social distancing. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765329 (2021). - PubMed
  35. Cassell, M. M., Halperin, D. T., Shelton, J. D. & Stanton, D. Risk compensation: the Achilles’ heel of innovations in HIV prevention? BMJ 332, 605–607 (2006). - PubMed
  36. Abu-Raddad, L. J. et al. Effect of vaccination and of prior infection on infectiousness of vaccine-breakthrough infections and reinfections. Preprint at medRxiv https://doi.org/10.1101/2021.07.28.21261086 (2021). - PubMed
  37. Abu-Raddad, L. J. et al. Association of prior SARS-CoV-2 infection with risk of breakthrough infection following mRNA vaccination in Qatar. JAMA (in the press). - PubMed
  38. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205–1211 (2021). - PubMed
  39. Seedat, S. et al. SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. Sci. Rep. 11, 18182 (2021). - PubMed
  40. Jeremijenko, A. et al. Herd immunity against severe acute respiratory syndrome coronavirus 2 infection in 10 communities, Qatar. Emerg. Infect. Dis. 27, 1343–1352 (2021). - PubMed
  41. Al-Thani, M. H. et al. SARS-CoV-2 infection is at herd immunity in the majority segment of the population of Qatar. Open Forum Infect. Dis. 8, ofab221 (2021). - PubMed
  42. Coyle, P. V. et al. SARS-CoV-2 seroprevalence in the urban population of Qatar: an analysis of antibody testing on a sample of 112,941 individuals. Iscience 24, 102646 (2021). - PubMed
  43. Jackson, M. L. & Nelson, J. C. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 31, 2165–2168 (2013). - PubMed
  44. Verani, J. R. et al. Case–control vaccine effectiveness studies: preparation, design, and enrollment of cases and controls. Vaccine 35, 3295–3302 (2017). - PubMed
  45. Butt, A. A. et al. SARS-CoV-2 vaccine effectiveness in preventing confirmed infection in pregnant women. J. Clin. Invest. https://doi.org/10.1172/JCI153662 (2021). - PubMed
  46. Vogels, C., Fauver, J. & Grubaugh, N. Multiplexed RT–qPCR to screen for SARS-COV-2 B.1.1.7, B.1.351, and P.1 variants of concern v3 ProtocolsIO https://doi.org/10.17504/protocols.io.br9vm966 (2021). - PubMed
  47. Saththasivam, J. et al. COVID-19 (SARS-CoV-2) outbreak monitoring using wastewater-based epidemiology in Qatar. Sci. Total Environ. 774, 145608 (2021). - PubMed
  48. Jacoby, P. & Kelly, H. Is it necessary to adjust for calendar time in a test-negative design? Responding to: Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine 2013;31(April (17)):2165-8. Vaccine 32, 2942 (2014). - PubMed
  49. Pearce, N. Analysis of matched case–control studies. BMJ 352, i969 (2016). - PubMed
  50. Rothman, K. J., Greenland, S. & Lash, T. L. Modern Epidemiology (Wolters Kluwer Health/Lippincott Williams & Wilkins, 2008). - PubMed
  51. StataCorp. Stata Statistical Software release 17 (StataCorp, 2021). - PubMed

Publication Types